Why Is Medivation at a Premium on an EV-to-EBITDA Basis?

This entry was posted by ctbenefits on April 15, 2016 at 9:46 am

Why Is Medivation at a Premium on an EV-to-EBITDA Basis?

Medivation is expanding the drug beyond prostate cancer treatment, and it plans to conduct a phase 3 trial for triple negative breast cancer (or TNBC) that would start in the second half of 2016. The company is conducting investigational studies for …

(Visited 2 times, 1 visits today)
Click here to read the full article
2
Like
Save

Comments

Write a comment